作者
Joyce F. Liu,Andrew Berchuck,Floor J. Backes,Joshua G. Cohen,Rachel N. Grisham,Charles A. Leath,Lainie P. Martin,Daniela Matei,David S. Miller,Sharon E. Robertson,Lisa Barroilhet,Shitanshu Uppal,Andrea Wahner Hendrickson,David M. Gershenson,Heidi J. Gray,Ardeshir Hakam,Angela Jain,Gottfried E. Konecny,John W. Moroney,Elena Ratner,John O. Schorge,Premal H. Thaker,Theresa L. Werner,Emese Zsíros,Kian Behbakht,Lee-may Chen,Marie DeRosa,Eric Eisenhauer,Gary S. Leiserowitz,Babak Litkouhi,Michael McHale,Sanja Percac‐Lima,Kerry Rodabaugh,Roberto Vargas,Frankie Jones,E Kovách,Lisa E. Hang,Swathi Ramakrishnan,Ronald D. Alvarez,Deborah K. Armstrong
摘要
The NCCN Guidelines for Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer provide multidisciplinary diagnostic workup, staging, and treatment recommendations for this disease. These NCCN Guidelines Insights detail how the evolution of the use of PARP inhibitors as maintenance and single-agent regimens for the treatment of ovarian cancer informed panel recommendations in the guidelines.
爱静静
加菲丰丰
有人
Singularity
shinysparrow
薰硝壤
寻道图强
乐乐乐乐乐乐
大卫在分享
pcr163
可口可乐了
景辣条
充电宝
浅尝离白
ShowMaker
AireenBeryl531
IBMffff
贰鸟
星辰大海
精明元霜
皖公网安备34019202002308
